Science Explorer Back to mapMap
Discussion
Company · Solna · Sweden

Kancera (Sweden)

kancera.comROR OpenAlex
Research works
10
▼ 53% vs 2018-21
Citations
124
12.1 per fractional work
Top-10% rate
16.6%
all institutions 10.0%
Open access
47%
world 40%
International
41%
world 18%
Kancera (Sweden)

Not ranked overall: Kancera (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Kancera (Sweden) work in?

In all years, 58% of research at Kancera (Sweden) is in Life Sciences, 39% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (40%), Medicine (39%), Immunology and Microbiology (12%). It does 2.0× the world's share of Life Sciences.

Life Sciences: 6 fractional works · 58.1% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 40.1% of its workMolecular Biology: 4 fractional works · 36.1% of its workBiotechnology: 0 fractional works · 1.7% of its workCell Biology: 0 fractional works · 1.7% of its workCancer Research: 0 fractional works · 0.8% of its workImmunology and Microbiology: 1 fractional works · 12.5% of its workImmunology: 1 fractional works · 12.2% of its workParasitology: 0 fractional works · 0.3% of its workNeuroscience: 0 fractional works · 3.9% of its workCellular and Molecular Neuroscience: 0 fractional works · 3.1% of its workNeurology: 0 fractional works · 0.8% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.7% of its workToxicology: 0 fractional works · 1.7% of its workHealth Sciences: 4 fractional works · 39.4% of its workMedicine: 4 fractional works · 39.4% of its workOncology: 2 fractional works · 14.7% of its workTransplantation: 1 fractional works · 9.7% of its workGenetics: 1 fractional works · 7.9% of its workEpidemiology: 0 fractional works · 1.8% of its workHematology: 0 fractional works · 1.8% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.5% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.8% of its workInfectious Diseases: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.4% of its workPhysical Sciences: 0 fractional works · 2.4% of its workEngineering: 0 fractional works · 2.4% of its workMechanical Engineering: 0 fractional works · 2.4% of its workALL ITS WORKKancera (Sweden)10fractional works, all years
Life Sciences58%Physical Sciences2%Health Sciences39%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 6 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology440.1%
    2. Immunology and Microbiology112.5%
    3. Neuroscience03.9%
    4. Pharmacology, Toxicology and Pharmaceutics01.7%
    1. Medicine439.4%
    1. Engineering02.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Kancera (Sweden)?

Ranked on the quality score, Johan Schultz and Thomas Olin lead among researchers whose main affiliation is Kancera (Sweden).

  1. 1 Johan Schultz Sweden · #2,086,567 worldwide 1.6k citations · 50 works
  2. 2 Thomas Olin Sweden · #3,257,528 worldwide 549 citations · 33 works
All ranked researchers at Kancera (Sweden)

What are the most cited papers from Kancera (Sweden)?

The most cited paper from Kancera (Sweden) is "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" (Nina Gustafsson et al., 2018), with 133 citations. Next come "Identification of novel quinazoline derivatives as potent antiplasmodial agents" (65) and "CD163+ macrophages monitor enhanced permeability at the blood–dorsal root ganglion barrier" (57).

Most cited papers
#PaperReleasedCitations
1 Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination Nina Gustafsson et al. · Nature Communications Open access 18 Sep 2018 133
2 Identification of novel quinazoline derivatives as potent antiplasmodial agents Anne Bouchut, Dante Rotili, Christine Pierrot et al. · European Journal of Medicinal Chemistry Open access 17 Oct 2018 65
3 CD163+ macrophages monitor enhanced permeability at the blood–dorsal root ganglion barrier Harald Lund, Matthew A. Hunt, Zerina Kurtović et al. · The Journal of Experimental Medicine Open access 28 Nov 2023 57
4 First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells Mohammad Hojjat‐Farsangi, Amir Hossein Daneshmanesh, Abdul Salam Khan et al. · Leukemia Open access 27 Mar 2018 54
5 A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib Amir Hossein Daneshmanesh, Mohammad Hojjat‐Farsangi, Amineh Ghaderi et al. · PLoS ONE Open access Jun 2018 45
All 30 most cited papers, with filters and sorting

Which research topics does Kancera (Sweden) publish most on?

By volume in 2022-now: Circular RNAs in diseases, Chronic Lymphocytic Leukemia Research, Mechanical Engineering and Vibrations Research and Phagocytosis and Immune Regulation.

Circular RNAs in diseases: 0 fractional worksChronic Lymphocytic Leukemia Research: 0 fractional worksMechanical Engineering and Vibrations Research: 0 fractional worksPhagocytosis and Immune …0Phagocytosis and Immune Regulation: 0 fractional worksGalectins and Cancer Biology: 0 fractional worksPI3K/AKT/mTOR signaling in cancer: 0 fractional worksHippo pathway signaling and YAP/TAZ: 0 fractional worksChronic Myeloid Leukemia Treatments: 0 fractional worksChemokine receptors and signaling: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional works
Molecular BiologyGeneticsMechanical EngineeringImmunology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Circular RNAs in diseases Molecular Biology 0 works
  2. 2 Chronic Lymphocytic Leukemia Research Genetics 0 works
  3. 3 Mechanical Engineering and Vibrations Research Mechanical Engineering 0 works
  4. 4 Phagocytosis and Immune Regulation Immunology 0 works
  5. 5 Galectins and Cancer Biology Immunology 0 works
  6. 6 PI3K/AKT/mTOR signaling in cancer Molecular Biology 0 works
  7. 7 Hippo pathway signaling and YAP/TAZ Cell Biology 0 works
  8. 8 Chronic Myeloid Leukemia Treatments Hematology 0 works
  9. 9 Chemokine receptors and signaling Oncology 0 works
  10. 10 Glycosylation and Glycoproteins Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available46.7%not open53.3%

World: 40% of research is openly available.

with international co-authors40.7%domestic only59.3%

World: 18% is written across borders.

How has Kancera (Sweden)'s research output changed?

Output in 2022-2025 was 53% lower than in 2018-2021.

20152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Kancera (Sweden) as a percentage of every work published that year, 0.000025% in 2023.

0.000020%0.000040%0.000060%Kancera (Sweden)0.0000085% in 20242020

Fractional works of Kancera (Sweden) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Solna

All research institutions in Solna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Kancera (Sweden). Posts are plain text and can be reported.